

Financial news for AKBA dated on 2020-06-10: Akebia Therapeutics Highlights Data On Different Dosing Regimens Of Ferric Citrate For Iron Deficiency Anemia Presented At ERA-EDTA Congress

Financial news for AKBA dated on 2020-05-18: Akebia Therapeutics Announces Filing of a Supplemental New Drug Application for Riona in Japan for Treatment of Patients with Iron Deficiency Anemia

Financial news for AKBA dated on 2020-05-12: 'This \$AKBA short report reads dumb to me, like someone drank too much coffee and got overly stimulated for nothing. But I'm willing to listen to a saner interpretation and change my mind' -Tweet From STAT News' Adam Feuerstein

Financial news for AKBA dated on 2020-05-12: Akebia Therapeutics Shares Tick Lower Following Tweet From Short Seller Muddy Waters 'Our PRTA short opened our eyes to the...world of misleading presentation of biotech trial data. No view / no position on AKBA, but it does raise similar questions'

Financial news for AKBA dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for AKBA dated on 2020-05-12: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AKBA dated on 2020-05-12: 32 Stocks Moving in Tuesday's Pre-Market Session

Financial news for AKBA dated on 2020-05-12: 5 Stocks To Watch For May 12, 2020

Financial news for AKBA dated on 2020-05-11: 14 Stocks Moving In Monday's After-Hours Session

Financial news for AKBA dated on 2020-05-11: Akebia Therapeutics shares are trading lower after the company announced a proposed \$100 million public offering of common stock.

Financial news for AKBA dated on 2020-05-11: Akebia Therapeutics Announces Proposed \$100M Public Offering of Common Stock

Financial news for AKBA dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for AKBA dated on 2020-05-06: JP Morgan Maintains Overweight on Akebia Therapeutics, Raises Price Target to \$18

Financial news for AKBA dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for AKBA dated on 2020-05-06: Morgan Stanley Maintains Equal-Weight on Akebia Therapeutics, Raises Price Target to \$11

Financial news for AKBA dated on 2020-05-06: H.C. Wainwright Maintains Buy on Akebia Therapeutics, Raises Price Target to \$17

Financial news for AKBA dated on 2020-05-06: 19 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for AKBA dated on 2020-05-06: Mizuho Maintains Buy on Akebia Therapeutics, Raises Price Target to \$17

Financial news for AKBA dated on 2020-05-06: 70 Biggest Movers From Yesterday

Financial news for AKBA dated on 2020-05-05: Needham Maintains Buy on Akebia Therapeutics, Raises Price Target to \$18

Financial news for AKBA dated on 2020-05-05: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AKBA dated on 2020-05-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for AKBA dated on 2020-05-05: Mid-Morning Market Update: Markets Open Higher; Sysco Misses Q3 Views

Financial news for AKBA dated on 2020-05-05: Recap: Akebia Therapeutics Q1 Earnings

Financial news for AKBA dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for AKBA dated on 2020-05-05: Akebia Therapeutics Q1 EPS \$(0.470) Beats \$(0.620) Estimate, Sales \$88.478M Beat \$77.480M Estimate

Financial news for AKBA dated on 2020-05-05: Akebia Therapeutics shares are trading higher after the company announced the results from its Phase 3 program of Vadadustat for treatment of Anemia achieved primary efficacy and cardiovascular safety endpoints.

Financial news for AKBA dated on 2020-05-05: Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Vadadustat Achieved Primary Efficacy And Cardiovascular Safety Endpoints

Financial news for AKBA dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for AKBA dated on 2020-03-16: Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for AKBA dated on 2020-03-11: Mizuho Reiterates Buy on Akebia Therapeutics, Lowers Price Target to \$15

Financial news for AKBA dated on 2020-03-10: Akebia Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Financial news for AKBA dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for AKBA dated on 2020-03-10: Akebia Therapeutics Q4 EPS \$(0.79) Misses \$(0.47) Estimate, Sales \$69.555M May Not Compare To \$93.15M Estimate

Financial news for AKBA dated on 2020-03-10: Earnings Scheduled For March 10, 2020

Financial news for AKBA dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for AKBA dated on 2020-02-25: Sarepta Shares Unaffected AS Hearing Vifor Has Confirmed Purchase Of Co.'s Priority Review Voucher

Financial news for AKBA dated on 2020-02-25: Shares of several healthcare companies are trading lower as markets fall amid the continued spread of the coronavirus, which has raised concerns of a global economic slowdown, impacting stocks across sectors.

Financial news for AKBA dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for AKBA dated on 2020-02-20: Stocks That Hit 52-Week Highs On Thursday

Financial news for AKBA dated on 2020-02-20: JP Morgan Maintains Overweight on Akebia Therapeutics, Raises Price Target to \$13

Financial news for AKBA dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for AKBA dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for AKBA dated on 2020-02-12: Stocks That Hit 52-Week Highs On Wednesday

Financial news for AKBA dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for AKBA dated on 2020-02-04: 85 Biggest Movers From Yesterday

Financial news for AKBA dated on 2020-02-03: Shares of several healthcare companies are trading higher in sympathy with the overall market on a rebound after increased fear of the Wuhan coronavirus' impact on the economy dropped the Dow roughly 600 points on Friday.

Financial news for AKBA dated on 2020-01-24: Shares of several companies in the healthcare and pharmaceutical space are trading lower, not currently seeing sector-specific news. NOTE: The global spread of the Wuhan coronavirus has caused equities across to sell off.

Financial news for AKBA dated on 2020-01-17: Akebia Therapeutics Option Alert: Jul 17 \$12.5 Calls at the Ask: 1000 @ \$0.71 vs 553 OI; Earnings 3/16 After Close [est] Ref=\$7.91

Financial news for AKBA dated on 2020-01-15: Shares of healthcare and pharmaceutical companies are trading higher, not currently seeing any sector-specific news. NOTE: U.S. equities are trading higher ahead of today's signing of the U.S.-China phase one trade deal.

Financial news for AKBA dated on 2019-12-10: Akebia Therapeutics shares are trading higher. Not currently seeing any news to justify the price action.

Financial news for AKBA dated on 2019-12-04: 63 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-12-03: Akebia Therapeutics shares are trading higher. Not currently seeing any news to justify the price action.

Financial news for AKBA dated on 2019-12-03: 75 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for AKBA dated on 2019-12-02: 52 Biggest Movers From Friday

Financial news for AKBA dated on 2019-11-29: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for AKBA dated on 2019-11-29: Akebia Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for AKBA dated on 2019-11-29: 52 Biggest Movers From Wednesday

Financial news for AKBA dated on 2019-11-26: Large Option Trader Betting On Biotech Stock Akebia Following Insider Buys

Financial news for AKBA dated on 2019-11-26: Akebia Therapeutics Option Alert: Dec 20 \$5 Calls Sweep (16) near the Ask: 606 @ \$0.451 vs 1090 OI; Ref=\$4.8

Financial news for AKBA dated on 2019-11-26: Akebia Therapeutics Option Alert: Dec 20 \$5 Calls Sweep (16) near the Ask: 606 @ \$0.451 vs 1090 OI; Ref=\$4.8

Financial news for AKBA dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-11-25: 50 Biggest Movers From Friday

Financial news for AKBA dated on 2019-11-22: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for AKBA dated on 2019-11-21: 63 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-11-20: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for AKBA dated on 2019-11-18: H.C. Wainwright Maintains Buy on Akebia Therapeutics, Lowers Price Target to \$16

Financial news for AKBA dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for AKBA dated on 2019-11-13: Stocks That Hit 52-Week Lows On Wednesday

Financial news for AKBA dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for AKBA dated on 2019-11-12: Akebia Reports Secured \$100M Non-Dilutive Term Loan Financing

Financial news for AKBA dated on 2019-11-12: Akebia Therapeutics Q3 EPS \$(0.46) Misses \$(0.43) Estimate, Sales \$91.98M Miss \$99.38M Estimate

Financial news for AKBA dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for AKBA dated on 2019-11-12: 58 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-11-10: The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

Financial news for AKBA dated on 2019-10-16: The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

Financial news for AKBA dated on 2019-09-11: Akebia Therapeutics On September 9 Entered Into Sublease With Foundation Medicine

Financial news for AKBA dated on 2019-09-11: 80 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for AKBA dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for AKBA dated on 2019-08-09: 110 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-08-08: Akebia Therapeutics shares are trading higher after the company reported Q2 EPS and sales increased 18.33% and 89.59% from the same quarter last year.

Financial news for AKBA dated on 2019-08-08: Akebia Therapeutics Q3 EPS \$(0.49) Up From \$(0.6) YoY, Sales \$100.803M Up From \$53.169M YoY

Financial news for AKBA dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for AKBA dated on 2019-08-06: Stocks That Broke Yearly Lows Tuesday Morning

Financial news for AKBA dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for AKBA dated on 2019-08-05: New 52-Week Lows For Monday Morning

Financial news for AKBA dated on 2019-08-05: Akebia Therapeutics Announces Settlement Of Auryxia Patent Litigation With Par Pharmaceutical

Financial news for AKBA dated on 2019-07-23: Akebia Therapeutics shares are trading higher after the company announced it submitted a Japanese New Drug Application for manufacturing and marketing approval of vadadustat as a treatment for anemia due to chronic kidney disease.

Financial news for AKBA dated on 2019-07-23: Akebia Therapeutics Announces Submission of Vadadustat NDA in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC

Financial news for AKBA dated on 2019-07-10: Akebia Therapeutics Highlights Collaboration Partners' Top-line Results Of Phase 3 Clinical Study Of Riona In Adult Patients With Iron Deficiency Anemia In Japan

Financial news for AKBA dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for AKBA dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for AKBA dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for AKBA dated on 2019-05-30: The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

Financial news for AKBA dated on 2019-05-29: The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Financial news for AKBA dated on 2019-05-09: Akebia Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.

Financial news for AKBA dated on 2019-05-09: Akebia Therapeutics Q1 EPS \$(0.62)

Misses \$(0.4) Estimate, Sales \$72.666M Miss \$81.02M Estimate

Financial news for AKBA dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for AKBA dated on 2019-05-02: Benzinga's Top Upgrades, Downgrades For May 2, 2019

Financial news for AKBA dated on 2019-05-02: Akebia Therapeutics shares are trading higher after JP Morgan started coverage on the stock with an Overweight rating.

Financial news for AKBA dated on 2019-05-02: Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation Of Four Posters At The NKF 2019 Spring Clinical Meetings

Financial news for AKBA dated on 2019-05-02: JP Morgan Initiates Coverage On Akebia Therapeutics, Inc. - Common Stock with Overweight Rating

Financial news for AKBA dated on 2019-04-10: Akebia 8-K Shows Supply Deal With Esteve Quimica For Manufacture Of Vadadustat Drug Substance For Commercial Use

Financial news for AKBA dated on 2019-04-10: UPDATE: Akebia Amended For License Deal With Vifor Subject To 3 Items

Financial news for AKBA dated on 2019-04-10: Akebia Therapeutics 8-K Shows Co., Vifor Amended License Deal For Exclusive License To Sell Fresenius Kidney Care Group

Financial news for AKBA dated on 2019-04-09: Vifor Pharma, Akebia Therapeutics Announce Expansion of License Agreement

Financial news for AKBA dated on 2019-04-03: 54 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-04-02: Akebia shares trading lower on no news catalyst. After shares rallied more than 70 percent from the lows set at the beginning of 2019, traders may be taking profits Tuesday, pushing the stock below the \$8 level.

Financial news for AKBA dated on 2019-03-20: Benzinga's Top Upgrades, Downgrades For March 20, 2019

Financial news for AKBA dated on 2019-03-20: Citigroup Initiates Coverage On Akebia Therapeutics with Neutral Rating, Announces \$9 Price Target

Financial news for AKBA dated on 2019-03-19: 36 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AKBA dated on 2019-03-19: The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

Financial news for AKBA dated on 2019-03-18: Akebia Therapeutics Q4 Sales \$59.85M Miss \$73.67M Estimate, Net Loss \$88.37M vs Gain Of \$15.5M In Same Qtr. Last Year

Financial news for AKBA dated on 2019-03-18: Earnings Scheduled For March 18, 2019

Financial news for AKBA dated on 2019-03-16: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for AKBA dated on 2019-03-13: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Mar. 13, 2019

Financial news for AKBA dated on 2019-03-13: 40 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AKBA dated on 2019-03-13: 56 Biggest Movers From Yesterday

Financial news for AKBA dated on 2019-03-12: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AKBA dated on 2019-03-12: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Mar. 12, 2019

Financial news for AKBA dated on 2019-03-12: Akebia Therapeutics shares are trading higher after the company announced that two pivotal Phase 3 studies of vadadustat in anemia patients with met their primary endpoints.

Financial news for AKBA dated on 2019-03-12: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AKBA dated on 2019-03-12: The Daily Biotech Pulse: Zafgen Won't

File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Financial news for AKBA dated on 2019-03-12: Akebia Therapeutics Announces Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease Met Primary Endpoints

Financial news for AKBA dated on 2019-02-27: Akebia Therapeutics Option Alert: Apr 18 \$7.5 Calls Sweep (2) near the Ask: 504 @ \$0.825 vs 635 OI; Earnings 3/11 After Close [est] Ref=\$7.227

Financial news for AKBA dated on 2019-02-25: 71 Biggest Movers From Friday

Financial news for AKBA dated on 2019-01-07: Akebia Therapeutics Says its Independent Data Monitoring Committee Recommended Protect and Innovate Programs Continue and Do Not Recommend Modifying Programs

Financial news for AKBA dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial